Sustainable biomanufacturing
The environmental case for fermentation-based peptide manufacturing.
Conventional peptide manufacturing through solid-phase peptide synthesis (SPPS) consumes thousands of litres of hazardous organic solvents per kilogram of product. Constructive.bio’s fermentation-based platform replaces this chemical process with E. coli fermentation in aqueous media, eliminating the dominant source of hazardous waste in peptide production while manufacturing on standard bioreactor infrastructure available at global scale.
SPPS process
Inputs
Outputs
Fermentation process
Inputs
Outputs
The Environmental Cost of SPPS
Solvent consumption per kilogram of crude peptide
5,000–15,000 L per kg
SPPS typically requires 5,000–15,000 litres of organic solvent per kilogram of crude peptide. For GLP-1 analogues at multi-tonne scale, this means millions of litres of hazardous waste annually per facility.
DMF restriction
SVHC under EU REACH
DMF classified as substance of very high concern (SVHC) under EU REACH. European Chemicals Agency has proposed restrictions. Supply chain risk for DMF-dependent manufacturers.
Energy intensity
Preparative HPLC at scale
Preparative HPLC purification is energy-intensive at manufacturing scale. Solvent recovery and waste treatment add further energy burden.
Waste classification
Hazardous
Majority of SPPS process waste classified as hazardous, requiring specialist treatment and disposal.
Peptide synthesis via SPPS is one of the most solvent-intensive processes in pharmaceutical manufacturing. Each coupling cycle requires repeated washes with DMF (dimethylformamide), NMP (N-methylpyrrolidone), and DCM (dichloromethane), followed by piperidine for Fmoc deprotection. A typical 30-residue peptide synthesis at laboratory scale consumes 1–2 litres of solvent per gram of crude product. At manufacturing scale, this ratio improves but remains substantial.
DMF and NMP are classified as substances of very high concern (SVHC) under EU REACH due to reproductive toxicity. DCM is a suspected carcinogen. Piperidine is regulated as a drug precursor. The combination of high volumes, hazardous classification, and specialist disposal requirements makes SPPS waste management a significant operational and regulatory burden.
Fermentation — A Different Footprint
What changes
- ✓No hazardous organic solvents in production — dominant liquid is water
- ✓Aqueous waste streams — biodegradable, non-hazardous, standard wastewater treatment
- ✓Standard fermentation infrastructure already installed globally
- ✓Sub-linear resource scaling — doubling output does not double solvent consumption because there is no solvent
What stays the same
- Downstream purification still uses solvents (acetonitrile, buffer systems) — common to both SPPS and fermentation. But purification burden is typically lower for fermentation due to higher sequence fidelity.
- Fermentation requires energy — carbon source production, sterilisation, water consumption.
- This is not zero-impact manufacturing. The claim is that fermentation eliminates the most problematic aspects (bulk hazardous solvent), not that it has no footprint.
The Scope 3 Argument
SPPS Route
Fermentation
Fermentation eliminates the three largest Scope 3 line items in peptide manufacturing
Pharmaceutical companies are required to quantify and report Scope 3 supply chain emissions under frameworks including the Corporate Sustainability Reporting Directive (CSRD) and International Sustainability Standards Board (ISSB). Peptide CDMO selection is increasingly influenced by the environmental profile of the manufacturing process — not as a secondary consideration, but as a procurement criterion with direct impact on reportable emissions.
SPPS-based contract manufacturers contribute significant Scope 3 emissions through organic solvent production (Category 1: purchased goods), solvent recovery energy (Category 3: fuel and energy), and hazardous waste transport and treatment (Category 5: waste). These are among the largest line items in peptide manufacturing emissions profiles. Fermentation eliminates the dominant contributor — bulk organic solvent — from the production process entirely.
For companies targeting carbon neutrality or Science Based Targets, selecting a fermentation-based manufacturing partner structurally reduces reportable Scope 3 emissions without requiring offsets. The reduction is inherent to the process, not dependent on renewable energy procurement or carbon credit markets.
Regulatory Tailwinds
EU REACH restrictions
Restriction proposals on DMF and NMP — two of the primary solvents in SPPS manufacturing.
EU Chemicals Strategy for Sustainability
Part of the European Green Deal, targeting hazardous industrial substances for phase-down or substitution.
FDA Green Chemistry initiative
Supporting fermentation and biocatalysis as alternatives to traditional chemical synthesis routes.
Pharma carbon neutrality targets
Novo Nordisk, Roche, and AstraZeneca have committed to Scope 3 reductions — supply chain sustainability is becoming a procurement criterion.
Sustainability by Design, Not Retrofit
Retrofit approach
- Solvent recovery (70–85% capture rate)
- Alternative green solvents
- Flow chemistry adaptations
- Carbon offset purchasing
→ Manages symptoms
Fermentation approach
- No organic solvents in production
- Aqueous process by design
- Standard bioreactor infrastructure
- No offsets required
→ Addresses cause
The environmental advantages of fermentation-based manufacturing are inherent to the process architecture. They are not add-on features, carbon offsets, or voluntary commitments. When the production process is fermentation in aqueous media rather than chemical synthesis in organic solvents, the solvent waste, hazardous classification, and associated emissions simply do not arise.
Retrofitting SPPS with green chemistry approaches — solvent recovery, alternative solvents, flow chemistry — addresses symptoms while the fundamental process architecture remains the same. Recovery rates for DMF are typically 70–85%, meaning significant volumes still enter the waste stream. Alternative solvents often introduce their own hazard profiles. Fermentation addresses the cause: the need for organic solvents is eliminated, not managed.
This creates alignment between manufacturing performance and environmental performance. The process that produces better peptides — higher fidelity, more ncAAs, scalable infrastructure — is also the process with the lower environmental footprint. Sustainability is not a trade-off; it is a structural advantage of the technology.
Frequently Asked Questions
How does fermentation reduce the environmental impact of peptide manufacturing?
Fermentation replaces organic solvents (DMF, NMP, DCM) with aqueous media for the production process. This eliminates thousands of litres of hazardous waste per kilogram of product. Waste streams from fermentation are biodegradable and treatable through standard wastewater infrastructure.
Does fermentation-based peptide manufacturing still use solvents?
Downstream purification uses acetonitrile and buffer systems, which is common to both SPPS and fermentation routes. The production process itself uses no hazardous organic solvents. The overall solvent burden is substantially reduced because the dominant solvent-intensive step — iterative amino acid coupling — is eliminated entirely.
How does choosing a fermentation-based CDMO affect Scope 3 emissions?
Fermentation eliminates the largest contributor to peptide manufacturing emissions: bulk organic solvent production, use, recovery, and disposal. This structurally reduces reportable Scope 3 purchased goods and services emissions compared to SPPS-based contract manufacturing partners.
Is DMF being restricted under EU REACH?
DMF (dimethylformamide) is classified as a substance of very high concern (SVHC) under EU REACH, and the European Chemicals Agency has proposed restrictions on its industrial use. Manufacturers dependent on DMF face regulatory compliance risk and potential supply chain disruption. Fermentation-based manufacturing avoids this entirely.
What is Constructive.bio’s approach to sustainability?
BioForge manufactures peptides through E. coli fermentation rather than chemical synthesis. This eliminates bulk hazardous solvent from the production process, produces biodegradable waste streams, and runs on standard bioreactor infrastructure. These advantages are inherent to the process architecture, not retrofitted sustainability measures.